ReviewRheumatic diseases clinics of North America2010
Microscopic polyangiitis.
Review in Rheumatic diseases clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 144 citations in OpenAlex.
- Antineutrophilic Cytoplasmic Antibodies Negative Vasculitic Neuropathy.Annals of African medicine · 2026Article
- Microscopic Polyangiitis in a Nonagenarian: Diagnostic and Therapeutic Challenges in Geriatric Vasculitis.Annals of geriatric medicine and research · 2026Article
- Aneurysmal rupture in microscopic polyangiitis: a case-based review.Clinical rheumatology · 2025Review
- Article
- Genetic and Non-Genetic Contributions to Eosinophilic Granulomatosis with Polyangiitis: Current Knowledge and Future Perspectives.Current issues in molecular biology · 2024Review
- Presentation and progression of MPO-ANCA interstitial lung disease.Journal of translational autoimmunity · 2024Article
- Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome.International journal of molecular sciences · 2024Review
- Advances in the Assessment and Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.Journal of inflammation research · 2024Review
- Fibrinogen induces inflammatory responses via the immune activating receptor LILRA2.Frontiers in immunology · 2024Article
- Profile, Healthcare Resource Consumption and Related Costs in ANCA-Associated Vasculitis Patients: A Real-World Analysis in Italy.Advances in therapy · 2023Article
- Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis.Journal of managed care & specialty pharmacy · 2023Article
- Neurogenic intermittent claudication caused by vasculitis in the cauda equina: an autopsy case report.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2023Article
- Article
- An unusual form of kidney injury without glomerulonephritis in microscopic polyangiitis: a case report.BMC nephrology · 2023Article
- New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond.Antibodies (Basel, Switzerland) · 2023Review
- Unilateral diffuse alveolar haemorrhage with microscopic polyangiitis: A case report.Respirology case reports · 2023Article
- Chronic cough and inflammatory bowel disease: an under-recognised association?Breathe (Sheffield, England) · 2023Article
- A modified renal risk score for Chinese patients with antineutrophil cytoplasmic antibody-associated vasculitis.BMC medicine · 2023Article
- A Case of Microscopic Polyangiitis Complicated by Mucormycosis: A Dangerous Balancing Act.Cureus · 2023Article
- Long-term clinical course and outcomes of patients with microscopic polyangiitis-associated interstitial lung disease.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In 1923, Friedrich Wohlwill described two patients with a "microscopic form of periarteritis nodosa," which was distinct from the classical form. This disease, now known as microscopic polyangiitis (MPA), is a primary systemic vasculitis characterized by inflammation of the small-caliber blood vessels and the presence of circulating antineutrophil cytoplasmic antibodies. Typically, microscopic polyangiitis presents with glomerulonephritis and pulmonary capillaritis, although involvement of the skin, nerves, and gastrointestinal tract is not uncommon. Treatment of MPA generally requires use of a cytotoxic agent (such as cyclophosphamide) in addition to high-dose glucocorticoids. Recent research has focused on identifying alternate treatment strategies that minimize or eliminate exposure to cytotoxic agents. This article reviews the history, pathogenesis, clinical manifestations, and treatment of MPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.